Should You Buy Goldman Sachs Stock After Its 26% Run-Up From Its 52-Week Low?

Goldman Sachs shares trade at $942, up about 26% from their October 2025 low but 18% below the July peak of $1,152, with the article characterizing the pullback as a buying opportunity at a 12.7x forward P/E. Q2 revenue rose 39% to a record $20.3 billion, investment-banking revenue increased 55%, and EPS surged 92% to $20.98, supported by a 48% year-over-year increase in first-half 2026 global M&A volume to $2.8 trillion. Goldman earned roughly $100 million advising on the SpaceX IPO and could receive a comparable or larger fee from Anthropic's expected October IPO, though a Fed rate increase and management's warning of slower Q3 trading revenue remain near-term headwinds.

Analysis

GS is now a high-beta expression of capital-markets activity rather than a simple value financial. The near-term issue is that underwriting fees from a single marquee IPO are economically immaterial versus quarterly revenue, while the signal value may already be embedded in expectations after the prior record quarter. A more consequential driver over the next 1-3 months is whether advisory backlog converts broadly and whether institutional trading normalizes; a sustained trading slowdown would reduce the earnings-quality premium investors assign to GS's operating leverage.

Relative to JPM and MS, GS has greater upside if the deal cycle remains strong because its revenue mix has more direct exposure to advisory and equity underwriting. That concentration also makes it more vulnerable if higher rates, renewed tariff uncertainty, or a weak IPO aftermarket causes boards to defer transactions; the same setup would favor JPM's more diversified net-interest-income and consumer franchises. The important second-order read-through is the performance of newly listed large-cap growth issues: weak post-IPO trading would pressure issuance calendars and syndicate economics well beyond any one mandate.

Consensus appears too focused on a headline IPO catalyst and a seemingly undemanding P/E. Bank valuations should be framed against normalized fee pools and returns, not peak-cycle quarterly EPS; multiple expansion requires evidence that deal activity is durable through 2027 rather than concentrated in a few mega-cap transactions. Falsify the cautious view if GS delivers fee-revenue growth excluding exceptional transactions while trading revenue stabilizes and management raises full-year efficiency or return targets.

Key Decisions for Investors

• Do not chase GS solely ahead of the expected October IPO; wait for post-deal aftermarket performance and Q3 segment disclosure. A weak debut or lower trading guidance would likely outweigh incremental underwriting fees over days to weeks.
• For a 1-3 month capital-markets recovery view, favor a pair trade long GS / short JPM in equal dollar amounts only if GS breaks above its post-earnings resistance on rising estimate revisions; GS offers greater fee-cycle torque, while JPM hedges broad bank-sector beta. Exit if GS investment-banking fees miss consensus or the relative spread closes by 8-10%.
• For a defensive 6-12 month view, own JPM over GS if rates remain restrictive or policy uncertainty rises: JPM's diversified earnings base should better absorb advisory and trading volatility. Reassess if GS demonstrates two consecutive quarters of broad-based fee growth rather than mandate-specific gains.
• Monitor IPO ETF proxies and major new-issue aftermarket returns through October. Sustained weakness in high-profile listings is a watch-item for reducing GS exposure, as it would signal lower issuance conversion and potentially compress forward earnings estimates.